Secondary endpoints: details revised at 3 of 20 entries
MinorStudy sites revised (19)v7
MinorStudy sites: 18 to 19v6
MinorTrial sites expanded: 4 → 18 locations
Start date changed from estimate of May 15, 2026 to Jul 1, 2026
v5
NotableRecruitment openedv4Show 4 more changesShow less
Start date: Mar 26, 2026 to May 15, 2026
Primary completion date: Jul 8, 2029 to Jul 10, 2029
Study completion date: Jul 8, 2030 to Jul 10, 2030
Site details revised at 4 of 4 sites
MinorTrial sites expanded: 0 → 4 locationsv3
MinorPrimary completion date: Jul 22, 2029 to Jul 8, 2029
Study completion date: Jul 22, 2030 to Jul 8, 2030
Start date: Feb 26, 2026 to Mar 26, 2026
v2
MinorStudy First Submitted
Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is an open-label, dose escalation and dose expansion study evaluating the safety, tolerability, Pharmacokinetic (PK), Pharmacodynamic (PD), and antitumor activity of PF-07994525 in participants with R/R MM.
The study will consist of 2 parts: Part 1 (Dose Escalation) will consist of PF-07994525 dose escalation to assess the safety, tolerability, and preliminary antitumor activity in participants with R/R MM. In Part 2 (Dose expansion), PF-07994525 may be evaluated in additional participants with R/R MM to further assess safety, PK, PD, and preliminary anti-tumor activity.